Risk factor
Very high price volatility
Profitability factor
Solid dividends
About
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu